Every year, hundreds of millions of dollars shift hands based on a single question: who filed first? The Paragraph IV […]

The $236 Billion Blind Spot Every supply chain director in pharmaceuticals knows the standard risks: a manufacturer fails a GMP

Generic drugs fill more than 90% of U.S. prescriptions yet capture only around 18% of total drug spending. That gap

The $300 Billion Window Procurement Teams Are Missing Between now and 2030, an estimated $300 billion in branded drug revenue

The pharmaceutical industry generates roughly $1.5 trillion in global revenues each year. It has survived opioid litigation, the Vioxx recall,

Every branded drug with a patent is also a clock. Somewhere in the FDA’s Orange Book, a set of expiration

Every biopharma patent filing is a confession. It tells you what a company believes is worth protecting, who did the

Every major drug company has a clock running in its boardroom. When a blockbuster patent expires, billions in annual revenue

In 2002, AbbVie launched adalimumab—a monoclonal antibody for rheumatoid arthritis sold under the brand name Humira—at a price of roughly